ArticleHuman vaccines & immunotherapeutics2026
Incidence and burden of hospitalizations for major respiratory infections among institutionalized adults followed by primary care residence units (UAR) in Madrid, Spain, September 2023-April 2025.
Article in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Institutionalized older adults bear a disproportionate burden of severe respiratory infections, but population-based data from long-term care facilities remain limited. We quantified the incidence and economic impact of hospitalizations attributable to influenza, COVID-19, respiratory syncytial virus (RSV), and pneumococcal disease among residents covered by the Unidades de Atención a Residencias (UAR) in the Community of Madrid. We performed a retrospective, population-based study linking primary care records (AP Madrid) and hospital discharge data (CMBD) for 40,660 institutionalized adults followed by UARs between September 2023 and April 2025. Hospitalizations with a primary diagnosis of COVID-19, influenza, RSV, or pneumococcal disease were identified using ICD-10 codes. Crude and age- and sex-adjusted hospitalization rates per 100,000 person-years were calculated using the mid-period institutionalized population (July 2024) as denominator, with 95% confidence intervals derived by standard methods. Total hospital costs were estimated by multiplying hospital days by pathogen-specific daily cost values. A total of 2,555 respiratory hospitalizations were identified: 1,102 (43.1%) influenza, 1,003 (39.3%) COVID-19, 289 (11.3%) pneumococcal disease, and 161 (6.3%) RSV, mostly among residents aged ≥80 y (78.4%). Crude hospitalization rates per 100,000 persons were 1,724.1 for COVID-19, 1,310.9 for influenza, 356.6 for pneumococcal disease, and 231.2 for RSV; adjusted rates were 986.7, 932.0, 212.3, and 145.4, respectively. Total hospital costs reached €11.08 million. Institutionalized adults in Madrid experience high hospitalization rates and substantial economic burden from respiratory infections, particularly those aged ≥80 y, highlighting the need for enhanced preventive strategies in long-term care facilities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.